G Protein-Coupled Receptor 120 Signaling Negatively Regulates Osteoclast Differentiation, Survival, and Function

Journal of Cellular Physiology

Volumn 231, Issue 4, 2016, Pages 844-851

  Kim, Hyun Ju ^a   Yoon, Hye Jin ^a   Kim, Bo Kyung ^a   Kang, Woo Youl ^a   Seong, Sook Jin ^a   Lim, Mi Sun ^b   Kim, Shin Yoon ^a   Yoon, Young Ran ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Yeungnam University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; COLONY STIMULATING FACTOR 1; G PROTEIN COUPLED RECEPTOR 120; I KAPPA B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT CELL 1; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; O3FAR1 PROTEIN, MOUSE; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE DESTRUCTION; BONE MARROW DERIVED MACROPHAGE; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL SPREADING; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BONE DEVELOPMENT; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; CYTOSKELETON; DRUG EFFECTS; GENETICS; METABOLISM; OSTEOLYSIS; PATHOLOGY; UPREGULATION;

ANIMALS; APOPTOSIS; BONE RESORPTION; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOSKELETON; MALE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84940773131     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25133     Document Type: Article

References (37)

1. Akiyama T, Bouillet P, Miyazaki T, Kadono Y, Chikuda H, Chung UI, Fukuda A, Hikita A, Seto H, Okada T, Inaba T, Sanjay A, Baron R, Kawaguchi H, Oda H, Nakamura K, Strasser A, Tanaka S. 2003. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 22:6653-6664.
2. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR, Glimcher LH. 2008. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118:3775-3789.
3. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
4. Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, Dunford JE, van der Does Y, Williams GA, Grey AB, Naot D, Reid IR. 2008. Modulation of osteoclastogenesis by fatty acids. Endocrinology 149:5688-5695.
5. Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. 2003a. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin. J Cell Biol 162:499-509.
6. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. 2003b. C-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 111:749-758.
7. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482-3496.
8. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. 2005. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90-94.
9. Hong JM, Teitelbaum SL, Kim TH, Ross FP, Kim SY, Kim HJ. 2011. Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation. J Bone Miner Res 26:657-665.
10. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, Kimura I, Leloire A, Liu N, Iida K, Choquet H, Besnard P, Lecoeur C, Vivequin S, Ayukawa K, Takeuchi M, Ozawa K, Tauber M, Maffeis C, Morandi A, Buzzetti R, Elliott P, Pouta A, Jarvelin MR, Korner A, Kiess W, Pigeyre M, Caiazzo R, Van Hul W, Van Gaal L, Horber F, Balkau B, Levy-Marchal C, Rouskas K, Kouvatsi A, Hebebrand J, Hinney A, Scherag A, Pattou F, Meyre D, Koshimizu TA, Wolowczuk I, Tsujimoto G, Froguel P. 2012. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483:350-354.
11. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappa B2. Nat Med 3:1285-1289.
12. Johnson RS, Spiegelman BM, Papaioannou V. 1992. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71:577-586.
13. Kim HJ, Hong JM, Yoon HJ, Kwon BM, Choi JY, Lee IK, Kim SY. 2014a. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption. Eur J Pharmacol 723:473-480.
14. Kim HJ, Hong JM, Yoon KA, Kim N, Cho DW, Choi JY, Lee IK, Kim SY. 2012. Early growth response 2 negatively modulates osteoclast differentiation through upregulation of Id helix-loop-helix proteins. Bone 51:643-650.
15. Kim HJ, Yoon HJ, Choi JY, Lee IK, Kim SY. 2014b. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity. J Leukoc Biol 95:337-345.
16. Kim HJ, Yoon HJ, Kim SY, Yoon YR. 2014c. A medium-chain fatty acid, capric acid, inhibits RANKL-induced osteoclast differentiation via the suppression of NF-kappaB signaling and blocks cytoskeletal organization and survival in mature osteoclasts. Mol Cells 37:598-604.
17. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL. 2006. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152-2160.
18. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. 2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433-440.
19. Novack DV, Teitelbaum SL. 2008. The osteoclast: Friend or foe?. Ann Rev Pathol 3:457-484.
20. Oh da Y, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, Sasik R, Hah N, Chi TJ, Cox JM, Powels MA, Di Salvo J, Sinz C, Watkins SM, Armando AM, Chung H, Evans RM, Quehenberger O, McNelis J, Bogner-Strauss JG, Olefsky JM. 2014. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20:942-947.
21. Oh DY, Lagakos WS. 2011. The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity. Curr Opin Clin Nutr Metab Care 14:322-327.
22. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. 2010. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:687-698.
23. Philippe C, Wauquier F, Leotoing L, Coxam V, Wittrant Y. 2013. GW9508, a free fatty acid receptor agonist, specifically induces cell death in bone resorbing precursor cells through increased oxidative stress from mitochondrial origin. Exp Cell Res 319:3035-3041.
24. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901.
25. Takeshita S, Kaji K, Kudo A. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15:1477-1488.
26. Talukdar S, Olefsky JM, Osborn O. 2011. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32:543-550.
27. Teitelbaum SL. 2007. Osteoclasts: What do they do and how do they do it?. Am J Pathol 170:427-435.
28. Teitelbaum SL, Ross FP. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
29. Wang JJ, Zhang LL, Zhang HX, Shen CL, Lu SY, Kuang Y, Wan YH, Wang WG, Yan HM, Dang SY, Fei J, Jin XL, Wang ZG. 2013. Gpr97 is essential for the follicular versus marginal zone B-lymphocyte fate decision. Cell Death Dis 4:e853.
30. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. 1992. Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741-745.
31. Wauquier F, Philippe C, Leotoing L, Mercier S, Davicco MJ, Lebecque P, Guicheux J, Pilet P, Miot-Noirault E, Poitout V, Alquier T, Coxam V, Wittrant Y. 2013. The free fatty acid receptor G protein- coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem 288:6542-6551.
32. Wellendorph P, Johansen LD, Brauner-Osborne H. 2009. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 76:453-465.
33. Wellhauser L, Belsham DD. 2014. Activation of the omega-3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons. J Neuroinflammation 11:60.
34. Wu Q, Wang H, Zhao X, Shi Y, Jin M, Wan B, Xu H, Cheng Y, Ge H, Zhang Y. 2013. Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene 32:5541-5550.
35. Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, Guarda G, Tian Z, Tschopp J, Zhou R. 2013. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38:1154-1163.
36. Yonezawa T, Kurata R, Yoshida K, Murayama MA, Cui X, Hasegawa A. 2013. Free fatty acids-sensing g protein- coupled receptors in drug targeting and therapeutics. Curr Med Chem 20:3855-3871.
37. Yore MM, Syed I, Moraes-Vieira PM, Zhang T, Herman MA, Homan EA, Patel RT, Lee J, Chen S, Peroni OD, Dhaneshwar AS, Hammarstedt A, Smith U, McGraw TE, Saghatelian A, Kahn BB. 2014. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159:318-332.